Jerome C. Landry, Yang Feng, Steven J. Cohen, Charles A. Staley III, Richard Whittington, Elin Ruth Sigurdson, Halla Nimeiri, Udit Verma, Roshan S. Prabhu and Al Bowen Benson Phase 2 study of preoperative radiation with concurrent capecitabine, oxaliplatin, and bevacizumab followed by surgery and postoperative 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX), and bevacizumab in patients with locally advanced rectal cancer: ECOG 3204 Cancer 119
Version of Record online: 3 JAN 2013 | DOI: 10.1002/cncr.27890
The addition of oxaliplatin and bevacizumab to fluoropyrimidine-based neoadjuvant chemoradiation for locally advanced rectal cancer resulted in pathologic tumor downstaging in the majority of patients, with a pathologic complete response rate of 17%. Increased wound healing delays and complications may have been related to the addition of bevacizumab, oxaliplatin, or both.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field